| Name | Title | Contact Details |
|---|
B. Braun is one of the world`s leading providers and manufacturers of healthcare solutions today. Every service that B. Braun provides incorporates the entirety of our knowledge and skills, the company`s deep understanding of users` needs, and more than 180 years of extensive expertise. With its constantly growing portfolio of effective medical care solutions, B. Braun makes a substantial contribution towards protecting and improving people`s health. In total, the B. Braun product range comprises 5,000 different products, 95 percent of which are manufactured by the company. By offering supplementary services and consulting, B. Braun is a system supplier that develops the best solution for patients in close partnership with our customers, making a significant contribution to medical advancements.
RAJA TRADING COMPANY is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NoIR Laser Company is a South Lyon, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mastercraft Dental Co of Texas is a Midlothian, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.